Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | APAF1 | O14727 | 2/20 | 0.48 |
| ▸ | MITF | O75030 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 3/20 | 0.44 |
| ▸ | CDC25A | P30304 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29926363 | 0.84 | MAPT (0.55) | MAPTALDH1A1LMNAHTTKDM4E | |
| SCHEMBL19886530 | 0.84 | MAPT (0.51) | MAPTALDH1A1LMNAHTTKDM4E | |
| SCHEMBL19875577 | 0.84 | MAPT (0.55) | MAPTALDH1A1LMNAHTTKDM4E | |
| SCHEMBL21940128 | 0.79 | MAPT (0.51) | MAPTALDH1A1LMNAHTTKDM4E | |
| SCHEMBL571484 | 0.78 | DHODH (0.60) | MAPTALDH1A1LMNAHTTKDM4E | |
| SCHEMBL13649352 | 0.78 | MAPT (0.51) | MAPTALDH1A1LMNAHTTKDM4E | |
| SCHEMBL5820368 | 0.76 | MAPT (0.58) | MAPTALDH1A1LMNAHTTKDM4E | |
| SCHEMBL11792639 | 0.75 | MAPT (0.52) | MAPTALDH1A1LMNAHTTKDM4E | |
| SCHEMBL11782376 | 0.74 | KDM4E (0.51) | MAPTALDH1A1LMNAHTTKDM4E | |
| SCHEMBL21650676 | 0.74 | MAPT (0.46) | MAPTALDH1A1LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2515896-B1 | ANTICOAGULANT COMPOUNDS AND THEIR USE | HAOMAMEDICA LTD (GB) | 2019-07-31 | — | — | EP | disclosed |
| US-20180092863-A1 | ANTICOAGULANT COMPOUNDS AND THEIR USE | HAOMA MEDICA LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| US-9622989-B2 | Treatment of osteoporosis | HAOMA MEDICA LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-9622989-B2 | Treatment of osteoporosis | HAOMA MEDICA LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| EP-2536398-B1 | TREATMENT OF OSTEOPOROSIS | HAOMAMEDICA LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| US-20150141339-A1 | TREATMENT OF OSTEOPOROSIS | HAOMA MEDICA LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-20150141339-A1 | TREATMENT OF OSTEOPOROSIS | HAOMA MEDICA LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8895624-B2 | Treatment of osteoporosis | Haoma Medica Ltd. (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895624-B2 | Treatment of osteoporosis | Haoma Medica Ltd. (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20130030050-A1 | TREATMENT OF OSTEOPOROSIS | HAOMA MEDICA LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030050-A1 | TREATMENT OF OSTEOPOROSIS | HAOMA MEDICA LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20120259007-A1 | ANTICOAGULANT COMPOUNDS AND THEIR USE | HAOMA MEDICA LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| US-20120259007-A1 | ANTICOAGULANT COMPOUNDS AND THEIR USE | HAOMA MEDICA LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| WO-2011077158-A1 | ANTICOAGULANT COMPOUNDS AND THEIR USE | HAOMAMEDICA LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011077159-A1 | TREATMENT OF OSTEOPOROSIS | HAOMAMEDICA LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141339-A1 | TREATMENT OF OSTEOPOROSIS | SOST, PTH1R, CYP24A1 | MAPT 2938/4885ALDH1A1 1641/4885LMNA 604/4885 |
| US-20180092863-A1 | ANTICOAGULANT COMPOUNDS AND THEIR USE | F2, F12, SERPINC1 | MAPT 4807/4885ALDH1A1 451/4885LMNA 336/4885 |
| US-20120259007-A1 | ANTICOAGULANT COMPOUNDS AND THEIR USE | F2, F12, SERPINC1 | MAPT 4807/4885ALDH1A1 451/4885LMNA 336/4885 |
| US-20130030050-A1 | TREATMENT OF OSTEOPOROSIS | SOST, PTH1R, CYP24A1 | MAPT 2938/4885ALDH1A1 1641/4885LMNA 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.